Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
$10.54+8.32%
报价 2026-11-06
市值
$886.6M
EV
$1.15B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -58.7%
$6.50$25.52
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CRVSCorvus Pharmaceuticals, Inc. | $886.6M | +8.3% | -133.3% | 0% | – | – | – | |
| ABSIAbsci Corporation | $1.75B | +8.3% | +2.8% | -255.9% | – | – | – | |
| VSTMVerastem, Inc. | $1.02B | -10.3% | +251.3% | 86.7% | – | – | – | |
| OLMAOlema Pharmaceuticals, Inc. | $641.4M | +8.4% | – | 0% | – | – | – | |
| RGNXREGENXBIO Inc. | $503M | +3.3% | +36.7% | 54.2% | – | – | – | |
| PRTAProthena Corporation plc | $409.2M | +1.0% | – | -208.6% | – | – | – | |
| CMPXCompass Therapeutics, Inc. | $136.7M | +10.8% | -125.5% | 0% | – | – | – | |
| AKBAAkebia Therapeutics, Inc. | $111.2M | -5.7% | -5.1% | 79.5% | – | – | 4.9x | |
| GOSSGossamer Bio, Inc. | $59.7M | +3.7% | -57.8% | 99.6% | – | – | – | |
| 同行中位数 | – | – | -1.1% | 27.1% | – | – | 4.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。